Supplementation of carnitine is the primary therapy for OCTN2 deficiency in which very low levels of free and acylated carnitine (<10 μmol/L) in plasma occur due to abnormally high urinary loss. Here, SLC22A5 is linked to hyperinsulinemic hypoglycemia, familial, 4.